Statute Details
- Title: Healthcare Services (Nuclear Medicine Service) Regulations 2023
- Act Code: HSA2020-S412-2023
- Type: Subsidiary Legislation (sl)
- Authorising Act: Healthcare Services Act 2020
- Enacting power: Minister for Health under section 57 of the Healthcare Services Act 2020
- Commencement: 26 June 2023
- Current version: Current version as at 27 Mar 2026
- Regulatory focus: Licensing and operational requirements for providing nuclear medicine services
- Key structure: Parts 1–10 plus a Schedule (specified services)
- Notable provisions (from extract): Definitions (s 2); application (s 3); specified services (s 5); prohibited service delivery modes (s 6); personnel and governance (ss 7–12); quality and equipment (ss 13–14); safety (ss 15–23); anaesthetics/sedatives (ss 24–33); testing and imaging (ss 34–38); imaging requirements (ss 39–51); in vivo assay (ss 52–61); therapy (ss 69–71); miscellaneous (ss 72–80)
What Is This Legislation About?
The Healthcare Services (Nuclear Medicine Service) Regulations 2023 (“Nuclear Medicine Regulations”) set out detailed, practice-level requirements for providers of nuclear medicine services in Singapore. In plain terms, the Regulations translate the broader licensing and healthcare governance framework in the Healthcare Services Act 2020 into specific rules that address the unique risks and workflow of nuclear medicine—particularly radiation safety, clinical governance, quality management, patient safeguards, and the handling and reporting of diagnostic and therapeutic outcomes.
The Regulations apply to “licensees” who provide nuclear medicine services at approved premises. They do not merely regulate the technical use of radiopharmaceuticals; they also regulate the organisational systems around that use. This includes requirements for qualified personnel, governance roles, quality management systems, equipment and fittings, safety programmes, and documentation and reporting obligations. The Regulations further differentiate between types of nuclear medicine services—imaging, in vivo assay, and therapy—because each has distinct clinical and operational risks.
Practically, a lawyer advising a healthcare operator, a corporate group, or a clinical governance team must treat these Regulations as a compliance blueprint. Non-compliance can create regulatory exposure under the Healthcare Services Act 2020, including enforcement actions and offences. The Regulations therefore matter not only for clinical staff, but also for corporate decision-makers responsible for licensing, staffing, outsourcing arrangements, and the integrity of clinical reporting.
What Are the Key Provisions?
1. Scope, specified services, and prohibited delivery modes
The Regulations begin with definitions and the basic application framework. Section 5 (as reflected in the extract) identifies the “specified services” for the purposes of section 9A(1) of the Healthcare Services Act 2020, by reference to the Schedule. This is important: the Schedule effectively determines what counts as a regulated nuclear medicine service under the licensing regime. Section 6 then addresses “prohibited service delivery modes”, signalling that the Regulations restrict how nuclear medicine services may be delivered (for example, whether certain modalities can be offered outside approved settings or through particular arrangements). For practitioners, the key compliance task is to map the operator’s actual service offerings to the Schedule and ensure the delivery model is permitted.
2. Personnel requirements and governance roles
Part 2 (ss 7–12) focuses on the people who must be in place. It requires qualifications, skills and competencies for a “Clinical Governance Officer” (s 7), and sets out that officer’s duties and responsibilities (s 8). The Regulations also require the appointment of a “section leader” (s 9) and define duties of that leader (s 10). While the extract does not reproduce the full text of these sections, the structure indicates a governance model: named roles with defined responsibilities, rather than purely informal oversight.
Section 11 provides general requirements relating to personnel, and section 12 addresses “specific personnel”. This likely includes additional staffing categories and competence expectations relevant to nuclear medicine practice. For legal counsel, the practical implication is that staffing compliance is not limited to having registered professionals; it includes ensuring the correct governance roles are appointed and that their responsibilities align with the Regulations’ requirements. Corporate governance and HR policies should therefore be reviewed alongside clinical protocols.
3. Quality management and equipment/fittings
Part 3 requires a “quality management system” (s 13) and sets requirements for “equipment and fittings” (s 14). These provisions are central to demonstrating that the service is delivered consistently and safely. A quality management system typically includes procedures for quality assurance, incident management, audits, corrective actions, and document control. Equipment and fittings requirements ensure that the physical infrastructure used for nuclear medicine examinations and related processes meets safety and operational standards.
4. Radiation and patient safety programmes
Part 4 (ss 15–23) is the heart of safety regulation. It requires a “safety programme” (s 15) and a “radiation safety programme” (s 16). Section 17 then requires the licensee to ensure personnel comply with the safety plans and programmes. Section 18 requires personal protective equipment to be provided. Sections 19–23 address operational safety around radiopharmaceutical administration and special patient categories and safeguards.
Notably, the Regulations include specific provisions for pregnant women (s 20), patients aged 12 years or younger (s 21), and adjunctive measures (s 22). Section 23 requires that essential life-saving measures must be available. These provisions reflect a risk-based approach: nuclear medicine procedures can involve radiation exposure and, depending on the radiopharmaceutical and clinical context, potential acute adverse events. The Regulations therefore require both preventive safeguards (e.g., for pregnancy and paediatric patients) and readiness for emergencies.
5. Anaesthetics and sedatives (where applicable)
Part 5 (ss 24–33) governs administration and use of anaesthetics and sedatives in the nuclear medicine context. It sets general requirements (s 25) and then addresses anaesthesia services (s 26), suitability of specified anaesthetics for the patient (s 27), nursing services (s 28), and essential life-saving measures (s 29). It also regulates post-procedure care (s 30), recovery and observation areas (s 31), discharge of patients (s 32), and post-discharge follow-up (s 33).
For practitioners, this Part is particularly important because it links clinical practice to safety infrastructure and patient flow. If a nuclear medicine service involves sedation or anaesthesia (for example, for paediatric imaging or specific diagnostic protocols), the operator must ensure compliance with the anaesthesia governance and patient monitoring requirements, including discharge and follow-up processes.
6. Testing of specimens and ultrasound imaging
Part 6 (ss 34–38) regulates testing of specimens and ultrasound imaging. It includes requirements for testing of specimens (s 34), instructions for self-collection by patients (s 35), conduct of simple in vitro diagnostic tests (s 36) and testing material for such tests (s 37), and conduct of ultrasound imaging (s 38). This indicates that nuclear medicine services may include diagnostic workflows beyond imaging alone, and that the Regulations cover both facility-based and patient-involved processes.
7. Imaging services: handling, referral, and reporting
Part 7 adds requirements for nuclear medicine services for imaging purposes. Section 39 sets the application of this Part. Division 1 includes rules on handling of images (s 40), general safeguards for examinations (s 41), and a key gatekeeping requirement: referral required before service provided to patients (s 42). It also regulates administration and use of contrast agents (s 43) and records for examinations (s 44).
Division 2 addresses reporting. It requires written imaging reports (s 46) and specifies contents (s 47). It also includes urgent notification in emergencies (s 48), processes for incidental or abnormal findings (s 49), notification of errors (s 50), and processes to ensure prompt reporting (s 51). These provisions are highly relevant to medico-legal risk: imaging reporting must be timely, accurate, and supported by appropriate documentation and escalation pathways.
8. In vivo assay services: specimen handling, accuracy, and reporting
Part 8 covers nuclear medicine services for in vivo assay purposes. Section 53 requires referral before service is provided. Division 1 includes acceptance and rejection of specimens (s 54), handling and transport (s 55), and accuracy requirements for applicable tests (s 56). It also sets standards for reagents (s 57), documentation relating to applicable tests (s 58), quality control (s 59), and records for specimens and applicable tests (ss 60–61). Division 2 then governs written clinical laboratory reports (ss 63–64), urgent notification (s 65), incidental/abnormal findings review (s 66), error notification (s 67), and prompt reporting processes (s 68).
9. Therapy services: counselling and protocols
Part 9 addresses nuclear medicine services for therapy purposes. It requires pre-treatment counselling and assessment (s 70) and post-treatment protocols (s 71). This reflects a patient-centred approach to therapeutic nuclear medicine, where informed consent and risk communication are critical, and where follow-up and safety protocols after treatment are essential.
10. Miscellaneous compliance: outsourcing, records, price transparency, and offences
Part 10 includes several compliance and enforcement-related provisions. Section 72 prohibits outsourcing (in the nuclear medicine context), which is a major operational constraint for corporate groups and service providers. Sections 73–74 require records relating to conduct of examinations, in vivo assay procedures, provision of treatment, and other matters. Sections 75–76 address price transparency and display of charges. Section 77 requires disclosure of approved institution status, and section 78 requires financial counselling.
Finally, section 79 provides for offences, and section 80 provides for revocation. For legal practitioners, these provisions underscore that compliance is enforceable and that corporate licensing status can be affected by breaches.
How Is This Legislation Structured?
The Regulations are structured into ten Parts:
Part 1 (Preliminary) sets citation/commencement, definitions, application, notification of additions/removals of purposes for which nuclear medicine service is provided, identification of specified services, and prohibited delivery modes.
Part 2 (Personnel) establishes governance roles (Clinical Governance Officer and section leader), their duties, and general/specific personnel requirements.
Part 3 (Processes, Equipment and Fittings) requires a quality management system and sets equipment/fittings requirements.
Part 4 (Safety Requirements) mandates safety and radiation safety programmes, PPE, safe administration of radiopharmaceuticals, and special safeguards for pregnant women and young patients, plus emergency readiness.
Part 5 (Anaesthetics and Sedatives) governs sedation/anaesthesia service requirements, patient monitoring, and discharge/follow-up.
Part 6 (Testing and Ultrasound Imaging) covers specimen testing, self-collection instructions, in vitro testing, and ultrasound imaging.
Part 7 (Imaging) contains additional requirements for imaging, including image handling, safeguards, referral requirement, contrast agent rules, record-keeping, and detailed reporting obligations.
Part 8 (In vivo assay) similarly sets specimen acceptance/transport, accuracy, reagents and quality control, records, and reporting requirements.
Part 9 (Therapy) focuses on counselling/assessment and post-treatment protocols.
Part 10 (Miscellaneous) addresses outsourcing prohibition, records, price transparency, disclosure of approved institution status, financial counselling, offences, and revocation.
Who Does This Legislation Apply To?
The Regulations apply to licensees who provide nuclear medicine services in Singapore at approved permanent premises. The compliance obligations are directed at the licensed entity, but they are operationally implemented through personnel, clinical governance roles, and service processes.
In addition, the Regulations impose patient-facing requirements indirectly through clinical workflows—such as referral requirements before service is provided (for imaging and in vivo assay Parts), special safeguards for pregnant women and young patients, and mandatory reporting and escalation processes. While the Regulations are not aimed at patients, they affect patient rights and safety through the provider’s obligations.
Why Is This Legislation Important?
These Regulations are important because nuclear medicine combines complex diagnostic/therapeutic procedures with radiation exposure and high stakes clinical decision-making. The Regulations therefore create a structured compliance environment: governance roles, quality systems, safety programmes, and reporting duties are designed to reduce the risk of harm and to ensure traceability and accountability.
From an enforcement and litigation perspective, the reporting and documentation provisions (particularly in imaging and in vivo assay Parts) are likely to be scrutinised in adverse outcome scenarios. Requirements for written reports, contents, urgent notification, incidental findings review, and error notification provide a clear standard of care for communication and escalation. Similarly, safety programme and PPE requirements provide a baseline for assessing whether the provider acted reasonably to manage radiation and procedural risks.
For practitioners advising operators, the Regulations also have corporate implications: the outsourcing prohibition (s 72) affects how services can be structured, while price transparency and financial counselling obligations (ss 75–78) affect billing and patient communication practices. Overall, the Regulations require integrated compliance across clinical operations, governance, documentation, and commercial conduct.
Related Legislation
- Allied Health Professions Act 2011
- Healthcare Services Act 2020
- Healthcare Services (General) Regulations 2021
- Medical Registration Act 1997
- Radiation Protection Act 2007
Source Documents
This article provides an overview of the Healthcare Services (Nuclear Medicine Service) Regulations 2023 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.